Winer EP, Lipatov O, Im SA, Goncalves A, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol 2021 Mar 4. pii: S1470-2045(20)30754.
PMID: 33676601